RayzeBio downgraded to Neutral from Overweight at JPMorgan
PremiumThe FlyRayzeBio downgraded to Neutral from Overweight at JPMorgan
11M ago
RayzeBio downgraded to Hold from Buy at Truist
Premium
The Fly
RayzeBio downgraded to Hold from Buy at Truist
11M ago
Gracell downgrade, Fusion upgrade: Wall Street’s top analyst calls
Premium
The Fly
Gracell downgrade, Fusion upgrade: Wall Street’s top analyst calls
11M ago
Bristol Myers price target lowered to $68 from $72 at BofA
PremiumThe FlyBristol Myers price target lowered to $68 from $72 at BofA
11M ago
RayzeBio downgraded to Market Perform from Outperform at William Blair
Premium
The Fly
RayzeBio downgraded to Market Perform from Outperform at William Blair
11M ago
M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B
Premium
Market News
M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B
11M ago
Bristol Myers to acquire RayzeBio for $62.50 per share in cash
PremiumThe FlyBristol Myers to acquire RayzeBio for $62.50 per share in cash
11M ago
Eight new option listings and one option delisting on November 8th
Premium
The Fly
Eight new option listings and one option delisting on November 8th
1y ago
RayzeBio announces FDA selected RYZ101 into CMC CDRP program
Premium
The Fly
RayzeBio announces FDA selected RYZ101 into CMC CDRP program
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100